Samsung Medical Center · Institution

Myung-Ju Ahn is one of Asia's most prolific lung cancer trialists, a steady presence on the steering committees of the EGFR, ALK, and immunotherapy trials that set today's standards.

Won Ki Kang

Professor of Medical Oncology; gastrointestinal oncology

Gastric cancerAdjuvant chemotherapyClinical trials

A senior gastric cancer oncologist whose adjuvant and perioperative trials in Korea helped define post-gastrectomy chemotherapy.

Woong-Yang Park

Director, Samsung Genome Institute; Professor of Molecular Cell Biology

Cancer genomicsSingle-cell sequencingPrecision oncology platforms

Built the genome institute behind Samsung Medical Center's precision oncology programme and its single-cell studies of tumours.

Yeon Hee Park

Professor of Medical Oncology; breast cancer programme

Breast cancerHER2-positive diseaseYoung-onset breast cancer

Leads breast medical oncology at Samsung Medical Center and has driven Korean participation in the HER2 and CDK4/6 trials that changed practice.

Key papers

1top

rctNew England Journal of Medicine 2023changed practice

DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer

Patients with small-cell lung cancer that has relapsed after chemotherapy now have a drug that works far better than topotecan or lurbinectedin, and it is the first T-cell engager approved for a solid tumour. Treatment requires inpatient monitoring for the first doses because of cytokine release syndrome, which most centres now manage on a short-stay basis. It does not yet apply to first-line treatment, where trials are ongoing.